On May 10, the FDA released guidance to drugmakers on what elements are needed for biosimilars to win approval as interchangeable drugs.  CP3 Associate Director Dr. Inma Hernandez spoke with Bloomberg Law's Jacquie Lee about how interchangeability might affect health plans.